SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-012867
Filing Date
2020-11-05
Accepted
2020-11-05 16:18:34
Documents
56
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q adap-20200930x10q.htm   iXBRL 10-Q 2026291
2 EX-31.1 adap-20200930xex31d1.htm EX-31.1 9824
3 EX-31.2 adap-20200930xex31d2.htm EX-31.2 10567
4 EX-32.1 adap-20200930xex32d1.htm EX-32.1 6138
5 EX-32.2 adap-20200930xex32d2.htm EX-32.2 6120
  Complete submission text file 0001558370-20-012867.txt   5304991

Data Files

Seq Description Document Type Size
6 EX-101.SCH adap-20200930.xsd EX-101.SCH 32087
7 EX-101.CAL adap-20200930_cal.xml EX-101.CAL 41932
8 EX-101.DEF adap-20200930_def.xml EX-101.DEF 82042
9 EX-101.LAB adap-20200930_lab.xml EX-101.LAB 296038
10 EX-101.PRE adap-20200930_pre.xml EX-101.PRE 204305
11 EXTRACTED XBRL INSTANCE DOCUMENT adap-20200930x10q_htm.xml XML 673803
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37368 | Film No.: 201290716
SIC: 2836 Biological Products, (No Diagnostic Substances)